Legend Biotech Corp ADR Dossier
Qualitative Analysis
Business overview
Legend Biotech Corp (NASDAQ: LEGN) is a leading global, clinical-stage biopharmaceutical company specializing in the discovery and development of novel cell therapies for oncology and other indications. The company's flagship product is CARVYKTI® (ciltacabtagene autoleucel), a highly efficacious B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy developed and commercialized in collaboration with Janssen Biotech (a Johnson & Johnson company). CARVYKTI® is approved for the treatment of relapsed or refractory multiple myeloma and has established a dominant position in the BCMA-targeted cell therapy market. Legend Biotech is leveraging its proprietary cell therapy platforms to expand its pipeline into other hematologic malignancies, solid tumors, and infectious diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding global manufacturing capacity to meet escalating demand for CARVYKTI, targeting a combined capacity of 10,000 doses annually by the end of 2025/2026. This includes operationalizing the Obelisc facility in Ghent, Belgium, and expanding the physical footprint of the Raritan, New Jersey facility.
Expected impact: Resolves autologous manufacturing capacity bottlenecks, stabilizes quarterly throughput, and supports global commercial rollout.
Advancing the company's proprietary in vivo CAR-T platform, led by LB2501, which targets CD19 and CD20 simultaneously. The platform aims to generate CAR-T cells directly inside the patient's body, eliminating the need for complex ex vivo manufacturing and lymphodepleting chemotherapy.
Expected impact: Establishes a highly scalable, next-generation cell therapy modality that addresses antigen-loss escape and simplifies treatment delivery.
Expanding the clinical pipeline beyond hematologic malignancies into solid tumors, which represent over 80% of the oncology market. Key programs include LB2102 targeting DLL3 for small cell lung cancer and LB1908 targeting Claudin 18.2 for gastric and pancreatic cancers.
Expected impact: Reduces single-product commercial concentration risk and establishes clinical proof-of-concept in difficult-to-treat solid tumors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Legend's most critical commercial relationship, governing the global development, manufacturing, and marketing of CARVYKTI. Legend receives a 50% share of gross profits from the collaboration.
Terms: Originally signed in December 2017 with a $350 million upfront payment. Legend continues to receive milestone payments, including $55 million achieved in April 2026.
Out-licenses Legend's DLL3-targeting CAR-T therapies, including LB2102. Novartis is responsible for global development, manufacturing (using its T-Charge platform), and commercialization, while Legend conducts the Phase I US trial.
Terms: Signed in November 2023 with a $100 million upfront payment and up to $1.01 billion in potential clinical, regulatory, and commercial milestones, plus royalties.